Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Coherus BioSciences

Gen Digital Inc

Lexicon Pharmaceuticals

Salarius Pharmaceuticals Inc

A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company’s future growth prospects.

5 Value Stocks In The Healthcare Sector

Here's Why Biogen Just Blew Its Q2 Earnings Out of the Water

Apple

Intel

Simon Property Group

GuruFocus users are buying Intel and Apple, according to new website feature.

The 4 Most-Voted Stocks in the Buying Basket as of July

CAMBRIDGE, Mass., July  24, 2020  (GLOBE NEWSWIRE) --  Biogen  (Nasdaq: BIIB) today announced there will be multiple data presentations from its Alzheimer’s disease (AD) clinical development portfolio, a virtual satellite symposium and AD PACE poster presentations at the Alzheimer’s Association International Conference (AAIC), which will be held online July 27-31. The company’s contributions to AAIC showcase its work to build a broad AD franchise across multiple targets and modalities, as well as to advance knowledge about early diagnosis, unmet patient needs and health system capacity to diagnose and treat people living with AD.

Biogen to Present Data at Virtual 2020 Alzheimer’s Association International Conference Highlighting Comprehensive Approach to Alzheimer’s Disease

Biogen Inc. (BIIB) CEO Michel Vounatsos on Q2 2020 Results - Earnings Call Transcript

The biotech, which specializes in treating neurological diseases, may have topped estimates, but its stock barely moved.

Biogen Beats Second-Quarter Expectations

Electronic Arts

Microsoft

S&P Global

VMware

Value stocks have been out of favor for a while – unless you know where to look. Our deep learning algorithms have been paired with our AI technology to identify the Top Quality Value stocks for July.

Top Value Stocks For July

Biogen earnings on Wednesday have BIIB stock higher after the company crushed Wall Street's expectations for EPS and revenue for the quarter.
The post Biogen Earnings: BIIB Stock Jumps 1% Higher on Q2 Beats appeared first on InvestorPlace.

Biogen Earnings: BIIB Stock Jumps 1% Higher on Q2 Beats

Biogen (BIIB) intends to start a phase IV study for the assessment of Spinraza's safety in infants and children with SMA who showed a suboptimal clinical response to Novartis' Zolgensma.

Biogen to Pit Spinraza Against Novartis' Zolgensma in Phase IV

Biogen (BIIB) beats second-quarter estimates for both earnings and sales. Stock rises.

Biogen (BIIB) Beats on Q2 Earnings, Raises EPS View, Stock Up

Biogen Inc. (NASDAQ: BIIB) published its quarterly earnings report on Wednesday that topped analysts’ estimates for earnings and revenue in the fiscal second quarter.

Biogen tops analysts’ estimates for earnings and revenue in Q2

Biogen earnings handily beat second-quarter views, while revenue narrowly beat. The biotech giant raised full-year EPS targets.

Biogen Earnings Easily Beat Views; Biotech Giant Rises

Shares of Biogen Inc. BIIB, -1.13% rose 1.4% in premraket trading Wednesday, after the biotechnology company reported second-quarter profit that rose well above expectations, and raised the full-year outlook.

Biogen's stock rises after big earnings beat, raised outlook

Drugmaker Biogen Inc beat analysts' estimates for quarterly profit on Wednesday on better-than-expected sales of its multiple sclerosis treatment Tecfidera, and boosted its 2020 profit outlook.

Biogen raises full-year profit view, quarter boosted by Tecfidera demand

Biogen Inc. BIIB, -1.13% said late Tuesday that Michael McDonnell will become chief financial officer on Aug. 15

Biogen names Michael McDonnell as new CFO

CAMBRIDGE, Mass., July  21, 2020  (GLOBE NEWSWIRE) --  Biogen Inc.  (Nasdaq: BIIB) announced today the appointment of Michael (Mike) McDonnell as Executive Vice President and Chief Financial Officer, effective August 15, 2020. McDonnell joins Biogen from IQVIA™ (NYSE: IQV), where he is Executive Vice President and Chief Financial Officer. At Biogen, McDonnell will lead the global finance function and operations, the Company’s shared services center, information technology and investor relations groups. He will report directly to Biogen’s Chief Executive Officer Michel Vounatsos, and will be based in Cambridge, Massachusetts.

Biogen Names Michael McDonnell as Executive Vice President and Chief Financial Officer

CAMBRIDGE, Mass., July  21, 2020  (GLOBE NEWSWIRE) --  Biogen  Inc.  (Nasdaq: BIIB) today announced it plans to initiate a global Phase 4 clinical study, RESPOND, to examine the clinical benefit and assess the safety of SPINRAZA® (nusinersen) in infants and children with spinal muscular atrophy (SMA) who still have unmet clinical needs following treatment with gene therapy Zolgensma® (onasemnogene abeparvovec).

Biogen Plans to Initiate Phase 4 Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated with Zolgensma® (onasemnogene abeparvovec)

Biogen submitted its application for approval of Alzheimer's treatment aducanumab in early July. And it's still targeting a coronavirus treatment with Vir.

Is Biogen Stock A Buy Now That Its Alzheimer's Drug Is In FDA's Court?

Biogen Inc (NASDAQ: BIIB) is caught in more than one legal wrangle with generic companies over patents related to its key multiple sclerosis drug Tecfidera, which was approved by the FDA in March 2013.

4 Ways Biogen's Tecfidera Generic Battle Could Play Out For The Stock

Goldman Sachs

Coca-Cola

Kroger

Sirius XM Holdings Inc

VeriSign

Warren Buffet has been an icon of Wall Street for decades. There’s no question about his investment acumen, given his track record and even the cost basis for many of his investments.

6 Warren Buffett Stocks That Could Soar as 2021 Approaches

A new phase III study has been initiated to evaluate Biogen (BIIB) and Eisai's BAN2401 to treat preclinical Alzheimer's disease.

Biogen/Eisai's New BAN2401 Study for Alzheimer's Begins

Biogen opened higher by around 10% on news of its Alzheimer's drug. By the end of day, BIIB stock gave up a bulk of its gains.

Potential Alzheimer’s Drug Not Enough to Excite Biogen Stock Investors

If Biogen's (BIIB) aducanumab is approved by the FDA, it will become the first medicine to be approved to reduce the clinical decline associated with Alzheimer's disease.

Biogen Files BLA for Alzheimer's Drug Aducanumab, Stock Up

CAMBRIDGE, Mass., July  08, 2020  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that positive results from a Phase 1/2 study of tofersen (BIIB067) for the potential treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS) were published in The New England Journal of Medicine. A mutation in the SOD1 gene is believed to be a genetic driver of disease in approximately two percent of all ALS cases.

The New England Journal of Medicine Publishes Final Results from Phase 1/2 Study of Tofersen for a Genetic Form of ALS

Snap

Twitter

Snap, Nio, Biogen and Twitter were our top stock trades for Thursday. That said, let's see how the charts are setting up after some big moves.

News for Biogen Stock (BIIB)